Navigation Links
Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
Date:3/4/2009

MOUNTAIN VIEW, Calif., March 4 /PRNewswire/ -- The Healthcare practice at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the North American biopharmaceuticals market to be held on Thursday, March 5, 2009 at 10:00 a.m. PST.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

The biopharmaceutical industry has witnessed healthy growth and is experiencing several notable trends, such as the increased use of contract manufacturing organizations and the targeting of biotechnology companies for mergers and acquisitions by pharmaceutical companies or other biotechnology companies. In addition, this industry faces issues that are immersed in heated debate, such as the approval pathway of biosimilars.

This briefing will benefit strategic planners, business development managers, research professionals, marketing managers, and those who are considering entering this dynamic market. Highlights of the briefing include an analysis of overall market trends, general market sizing, and a look at selected issues.

"One of the hot topics in the biopharmaceutical market is the ethical debate surrounding the research and use of embryonic stem cells," notes Frost & Sullivan Research Analyst Katheryn Symank. "This issue is immersed in both political and ethical controversy. Some argue that the use of human embryonic stem cells is unethical while others support their use because of the potential medical good to the population."

To participate, please email Stephanie Ochoa, Corporate Communications, at stephanie.ochoa@frost.com with the following information: your full name, title, company name, company telephone number, company email address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:

    Stephanie Ochoa
    Corporate Communications - North America
    P: 210.247.2421
    F: 210.348.1003
    E: stephanie.ochoa@frost.com
   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
2. Pioneer(R) Surgical Technology, Inc. Wins Frost & Sullivans 2009 North American Orthopaedic Tissue Engineering Technology Innovation Award
3. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
4. Frost & Sullivan Forecasts Early Rebound: Strong Growth Ahead for Global Economy
5. Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma
6. Frost & Sullivan Recognizes ESBATechs Innovation in Developing Antibody Fragments for Biologic Therapeutics
7. Ganeden Biotech Receives Frost & Sullivan Probiotics Product Innovation Award
8. Frost & Sullivan Commends Honeywell Enraf for Cutting-Edge Products and Post-Sales Support
9. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
10. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
11. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- The Board of Directors of the Pittsburgh Life ... only pure life sciences investment firm, today announced ... plan developed by the Nominating and Governance Committee over ... F. Jordan is selected to serve as President ... , who is elected to the position of Executive ...
(Date:12/8/2016)... 2016  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... cancer immunotherapies, today announced financial results for the ... are delivering on our commitment to address an ... We are pleased with the early clinical response ... we are focused on advancing our lead program ...
(Date:12/8/2016)...  Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...
(Date:12/8/2016)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... circuits with very high precision light to control cells — optogenetics — is ... In the current state of the art, spatially patterned light projected via free-space ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... 30, 2016 Not many of us realize that we spend ? of ... we need to do it well. Inadequate sleep levels have been found to lead ... diabetes, and even cancer. Maybe now is the best time to rethink ... them to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
Breaking Biology News(10 mins):